Novo Nordisk A/S Class B · OMXCOP:NOVO_B

Novo Nordisk A/S Class B — Bear Stearns Healthcare Conference 2007

48 slides from Novo Nordisk A/S Class B's conference presentation, Feb 27, 2007

  1. Slide 1: Bear Stearns Healthcare Conference

    Bear Stearns Healthcare Conference Bear Stearns Healthcare Conference Jakob Riis Senior Vice President, International Marketing London, 27 February 2007

  2. Slide 2: Forward-looking statements

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 2 Forward-looking statements The above contains forward-looking statements as the term is defined in the US Private Securities Litigation Reform Act of 1995. This in particular relates to information included under the headings ‘Outlook 20

  3. Slide 3: Agenda

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 3 Agenda • Highlights and strategy • Sales update • R&D update • Financials

  4. Slide 4: Highlights for 2006

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 4 Highlights for 2006 Market development: • Robust sales growth: +15% as reported, +16% in local currencies • Sales growth driven by modern insulins: +48% as reported • NovoSeven® growth continued: +11% as reported • Norditropin® showed st

  5. Slide 5: Highlights for 2006, cont’d

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 5 Highlights for 2006, cont’d R&D – diabetes care: • Recruitment completed in global liraglutide phase 3 study • Initiation of phase 3 study of liraglutide in Japan • Initiation of phase 2 dose-ranging study of liraglutide within obesity •

  6. Slide 6: Novo Nordisk’s corporate strategy

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 6 Novo Nordisk’s corporate strategy Focus areas Compounds/Capabilities Strategic focus Insulin Drug delivery and protein expertise 1. Diabetes Maintain Leadership GLP-1 Global specialist reach Other proteins rFVIIa 2. Biopharmaceuticals rF

  7. Slide 7: Insulin world market leader with 52% market share

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 7 Insulin world market leader with 52% market share Europe North America Novo Nordisk #1 Novo Nordisk #1 Market share 57% Japan & Oceania Market share: 41% Novo Nordisk #1 Market share: 76% International Operations Novo Nordisk #1 Market s

  8. Slide 8: Growth in Novo Nordisk’s insulin franchise looks set to continue

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 8 Growth in Novo Nordisk’s insulin franchise looks set to continue IMS developed world insulin Rapid increase in number of market growth people with diabetes Volume: 5.4% 200 2007 2025 180 Value: 160 2007: 246 million 10.9% 140 2025: 380 m

  9. Slide 9: Sales update

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 9 Sales update

  10. Slide 10: Key products continue to drive growth – full year 06

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 10 Key products continue to drive growth – full year 2006 Sales as reported Growth analysis Other Norditropin® +2% Local currencies Growth Share of +19% growth 5% 9% Diabetes care Modern insulins 50% 69% +16% Human insulin and 1% 3% NovoSe

  11. Slide 11: Modern insulins

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 11 Modern insulins Modern insulin sales development Modern insulin sales as reported Levemir® +40% DKK 1.4bn 3,200 +187% NovoRapid® DKK 5.6bn 2,800 13% NovoMix® +36% 2,400 DKK 3.8bn DKK million +42% 2,000 35% 52% 1,600 1,200 800 400 0 Q1 Q

  12. Slide 12: A continued increase in modern insulin market share

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 12 A continued increase in modern insulin market share IMS world modern insulin Modern insulin penetration market shares, volume 80% 70% Novo Nordisk 60% Eli Lilly 49% Modern insulin 50% Sanofi-Aventis 7% 40% 30% Human insulin 20% 10% 0% Q

  13. Slide 13: Levemir reinforces European modern insulin market leadership

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 13 Levemir® reinforces European modern insulin market leadership Share of total modern insulin Novo Nordisk’s share of long- sales in Europe acting modern insulin in Europe 21% 22% 60% Novo Nordisk Eli Lilly 20% Sanofi-Aventis 18% 50% 16%

  14. Slide 14: NovoSeven sales development

    DKK million 0 200 400 600 800 1,000 1,200 1,400 1,600 Q1 2002 NovoSeven® NovoSeven® sales development Q4 2006 +6% Key observations • Growth in the fourth quarter of 6% as reported, 11% in local Bear Stearns Healthcare Conference currencies • Sales growth in all regions • North American sales picked

  15. Slide 15: Norditropin sales development

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 15 Norditropin® Norditropin® Global growth hormone sales development market shares, value 60% Pfizer Novo Nordisk +15% Genentech 900 50% Eli Lilly 800 Serono 700 40% DKK million 600 28% 500 30% 23% 400 20% 300 200 10% 100 0 0% Q1 Q4 Q1 Q3

  16. Slide 16: Sales by region – full year 2006

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 16 Sales by region - full year 2006 Sales as reported Growth analysis Japan & Oceania -1% Europe Local Growth Share of +9% currencies growth 12% International Europe 9% 23% Operations North America 29% 53% +17% 18% 38% International 17% 20

  17. Slide 17: US diabetes performance

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 17 US insulin market share US diabetes performance development Novo Nordisk’s US insulin sales development Index 80% local currencies 70% Novo Nordisk 500 Eli Lilly 450 60% Sanofi-Aventis 400 % : 43 50% 350 AGR C 300 40% 250 200 30% 150 20

  18. Slide 18: Levemir launch in the US

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 18 Levemir® launch in the US • High level of formulary coverage: • Increase in US sales force by 700 Levemir® share of total basal close to 75% of total lives at Key observations modern insulin prescriptions to 1,900 to drive further 6% pe

  19. Slide 19: R&D update

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 19 R&D update

  20. Slide 20: Development portfolio – diabetes

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 20 Development portfolio – diabetes Compound Type Indication Phase Levemir® Modern insulin Types 1+2 Launched in US, Europe, etc. Filed in JP NovoMix® 50 and 70 Modern insulin Types 1+2 Approved in Europe Filed in US Liraglutide GLP-1 anal

  21. Slide 21: Development portfolio – haemostasis

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 21 Development portfolio – haemostasis Compound Indication Phase NovoSeven® Heat-stable formulation Preparing for filing NovoSeven® Intracerebral haemorrhage Phase 3 NovoSeven® Trauma Phase 3 NovoSeven® Prophylaxis Phase 2 completed NovoSe

  22. Slide 22: Development portfolio - other biopharmaceuticals

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 22 Development portfolio - other biopharmaceuticals Compound Indication Phase Activelle® low dose Hormone replacement therapy Approved in US; Filed in Europe Vagifem® low dose Hormone replacement therapy Phase 3 Norditropin® APCD1 Phase 2

  23. Slide 23: Financials

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 23 Financials

  24. Slide 24: Financial results

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 24 Financial results DKK million 2006 2005 % change Sales 38,743 33,760 15 Gross profit 29,158 24,583 19 Gross margin 75.3% 72.8% Sales and distribution costs 11,608 9,691 20 Percent of sales 30.0% 28.7% Research and development costs 6,31

  25. Slide 25: Strong gross margin development

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 25 Strong gross margin development Gross margin improvement analysis Key observations 76% • Underlying improvement of 210 bp basis points 1 0 75% +2 75.3 • Productivity gains prime 74% bp contributor – reflecting significant 0 73.2 +9 0.4

  26. Slide 26: Long-term financial targets

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 26 Long-term financial targets Long-term financial targets In % Financial 2002 2003 2004 2005 2006 targets Operating profit growth 9.6 8.4 8.7 15.9 12.7 15 Operating margin 23.8 24.6 24.0 24.0 23.5 25 Cash to earnings* 12.1 79.6 85.3 82.4

  27. Slide 27: Outlook 2007

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 27 Outlook 2007 • Sales growth expectations: • More than 10% measured in local currencies Key currency rates • Sales growth in DKK lower than sales growth in DKK 2006 2007 Current local currencies per 100 averag average rate* e • Operating

  28. Slide 28: Novo Nordisk - concluding remarks

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 28 Novo Nordisk - concluding remarks • #1 in the global injection device • #1 in the global modern insulin • #1 in the global insulin market Key growth drivers • #1 in the global haemophilia • Leadership in diabetes care with Strategic pos

  29. Slide 29: Investor information

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 29 Investor information Share information Investor Relations Novo Nordisk’s B shares are contacts listed on the stock exchanges in Novo Nordisk A/S Investor Relations Copenhagen and London. Its Novo Allé, DK­2880 Bagsværd Fax (+45) 4443 66

  30. Slide 30: Appendices

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 30 Appendices

  31. Slide 31: Currency development: USD and JPY

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 31 Currency development: USD and JPY Spot rates Quarterly average Annual average 660 628 640 621 USD/DKK 620 612 600 577 573 580 592 594 586 560 568 540 Q105 Q205 Q305 Q405 Q106 Q206 Q306 Q406 6.0 Spot rates Quarterly average Annual averag

  32. Slide 32: Solid insulin market growth - Novo Nordisk market leadership

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 32 Solid insulin market growth - Novo Nordisk market leadership Market size Growth rates Novo Nordisk market share Market Novo Nordisk US 11.2% 41% 39% 3.9% Europe 4.1% 51% 57% 5.6% Japan 7.1% 74% 5% 7.2% World 6.6% 52% 100% 5.0% Note: Vol

  33. Slide 33: Insulin growth driven by NovoRapid and NovoMix

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 33 Insulin growth driven by NovoRapid® and NovoMix® NovoRapid® share of short- NovoMix® share of acting modern insulin premixed modern insulin 70% 70% 66% 60% 60% 53% 50% 50% 40% 40% 30% 30% 20% 20% 10% 10% 0% 0% Q1 Q3 Q1 Q3 2002 2006 2002

  34. Slide 34: European modern insulin conversion - NovoRapid

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 34 European modern insulin conversion - NovoRapid® Modern insulin penetration short-acting modern insulin Share of short-acting segment NovoRapid® 30% 25% Human insulin 20% Humalog 55% 15% 10% Modern insulin 5% Apidra 0% Q1 Q3 Q1 Q3 2000 2

  35. Slide 35: European modern insulin conversion - NovoMix

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 35 European modern insulin conversion - NovoMix® 30 Modern insulin penetration premixed segment Share of premixed segment 25% 20% NovoMix® 30 Human insulin 15% 10% Humalog Mix 25 5% 35% Modern insulin 0% Q1 Q3 Q1 Q3 2000 2006 2000 2006 Not

  36. Slide 36: European modern insulin conversion - Levemir

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 36 European modern insulin conversion - Levemir® Modern insulin penetration Novo Nordisk’s share of long- long-acting segment acting modern insulin in Europe 22% 21% 20% 18% 16% Human insulin 14% 12% 10% 8% 47% 6% 4% 2% Modern insulin 0% Q

  37. Slide 37: US modern insulin conversion - NovoLog

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 37 US modern insulin conversion - NovoLog® Modern insulin penetration short-acting segment Share of short-acting segment 50% Human insulin 40% Humalog 67% 30% NovoLog® 20% 33% Modern insulin 10% 0% Q1 Q3 Q1 Q3 2000 2006 2000 2006 Note: Qua

  38. Slide 38: US modern insulin conversion - NovoLog Mix 70/30

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 38 US modern insulin conversion - NovoLog® Mix 70/30 Modern insulin penetration premixed segment Share of premixed segment 30% 25% Humalog Mix 25 Human insulin 20% 15% NovoLog® Mix 70/30 10% 31% 5% Modern insulin 0% Q1 Q3 Q1 Q3 2000 2006 2

  39. Slide 39: US modern insulin conversion - Levemir

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 39 US modern insulin conversion - Levemir® Modern insulin penetration Levemir® share of total long-acting long-acting segment modern insulin prescriptions 6% 5% Human insulin 4% 3% 60% 2% 1% Modern insulin 0% Q1 Q3 April December 2000 2006

  40. Slide 40: Insulin segmentation - Europe and the US

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 40 Insulin segmentation - Europe and the US Europe US 60% 60% 50% 50% 40% 40% 30% 30% 20% Long-acting 20% Long-acting Premix Premix 10% 10% Short-acting Short-acting 0% 0% Q1 Q3 Q1 Q3 2000 2006 2000 2006 Note: Quarterly data, volume figure

  41. Slide 41: Switch from Lantus to Levemir improved HbA1c, while reducing hypoglycaemia and weight

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 41 Switch from Lantus to Levemir® improved HbA1c, while reducing hypoglycaemia and weight 10 No. hypoglycaemic episodes /patient year 7.8 HbA1c change: -0.59 %-points vs. Lantus Change in body weight: -0.8 kilograms 2.2 * 0.5 * * 0.1 0.3 0

  42. Slide 42: Human versus all-analogue basal-bolus in type 1 diabetes

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 42 Human versus all-analogue basal-bolus in type 1 diabetes: Switch to Levemir® + NovoRapid® 60 55 No. hypoglycaemic episodes/patient year 50 HbA1c change (%-points): -0.65 vs. human basal-bolus 40 30 20 18.3 * 11 10 * * 1.7 1.2 0.0 0 Over

  43. Slide 43: Biosimilars compete in a declining segment

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 43 Biosimilars compete in a declining segment Modern insulin conversion in IMS world markets Modern insulin 49% Patent protected Human insulin 2000 Q3 2006 2011 Notes: Quarterly data based on volume figures. From Q3 2006 onwards it is esti

  44. Slide 44: Insulin is the ultimate treatment

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 44 Insulin is the ultimate treatment Insulin is the ultimate treatment Key observations • A clear focus on the need for intensifying treatment of diabetes, both via the use of OADs and insulin -Cell function • The number of type 2 patient

  45. Slide 45: Insulin secretion

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 45 Insulin secretion 800 People without diabetes Insulin Secretion (pmol/min) 700 Type 2 diabetes 600 500 400 300 200 100 0600 1000 1400 1800 2200 0200 0600 Source: O'MEARA et al. Am. J. Medicine, 1990; 89.

  46. Slide 46: Attractive profile of rFVIIa analogue

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 46 Attractive profile of rFVIIa analogue Velocity (mm*100/sec) 20 Severe haemophilia A + rFVIIa 2 µg/mL + NN1731 2 µg/mL • NN1731 has been found to 15 Healthy male induce a faster rate of thrombin formation than 10 obtainable with NovoSeve

  47. Slide 47: Faster haemostasis leads to - a unique mechanism of action

    FVIIa/NovoSeven® NovoSeven® A bleeding episode Tissue factor Faster haemostasis leads to • Fewer transfusions / transfusion- free surgery Bear Stearns Healthcare Conference • Reduced re-bleeding • Faster recovery • Reduced morbidity and mortality 27 February 2007 • Improved quality of life Slide no

  48. Slide 48: Anti-KIR being developed in collaboration with Innate Pharma

    Bear Stearns Healthcare Conference 27 February 2007 Slide no 48 Anti-KIR being developed in collaboration with Innate Pharma Mode of action Key observations Anti-KIR MoA • Unmet need in AML Tumour • Most common leukaemia in NK Cell adults: around 12,000 new cases per year in the US of which 75% die

Novo Nordisk — Bear Stearns Healthcare Conference 2007 on 6ix